Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer’s disease and three causality networks of AD: the GR@ACE project

Background Genetics plays a major role in Alzheimer’s Disease (AD). To date, 40 genes associated with AD have been identified, although most remain undiscovered. Clinical, neuropathological and genetic variability might impact genetic discoveries and complicate dissection of the biological pathways underlying AD. Methods GR@ACE is a genome-wide study of dementia and its clinical endophenotypes that encompasses 4,120 cases and 3,289 controls from Spain. GR@ACE phenotypes were defined according to AD’s clinical certainty and the presence of vascular co-morbidity. To explore whether clinical endophenotypes reflect variation in underlying biological pathways, we first assessed the impact of known AD loci across endophenotypes to generate three loci categories. Next, we incorporated gene co-expression data and conducted pathway analysis on each category. To assess the impact of heterogeneity in the GWAS findings, the GR@ACE series were meta-analyzed with: 1) genotype-level data from dbGaP (N=21,235); and 2) summary statistics from IGAP Stages I and II (n=61,571 and n=81,455 respectively). Findings We classified known AD loci in three categories, which might reflect the disease clinical heterogeneity, from vascular and mixed forms to pure AD pathology. Immune system pathways were detected in all categories. Intriguingly, vascular processes were only detected as a causal mechanism in probable AD. A meta-analysis of GR@ACE with additional GWAS datasets revealed the ANKRD31-rs4704171 signal in the HMGCR genomic region. We confirmed NDUFAF6-rs10098778 and SCIMP-rs7225151, which were previously detected by IGAP, to be suggestive signals. We also confirmed CD33-rs3865444 to be genome-wide significant. Interpretation The regulation of vasculature is a prominent causal component of probable AD. In that context, cerebral amyloid angiopathy, the unique identified link between the vascular and amyloid hypotheses, deserves further investigation. The GR@ACE meta-analysis revealed novel AD genetic signals. GWAS results are strongly driven by the presence of clinical heterogeneity in the AD series. Funding Grifols SA, Fundación bancaria “La Caixa”, Fundació ACE and ISCIII (Instituto de Salud Carlos III).

[1]  S. Leurgans,et al.  Attributable risk of Alzheimer's dementia attributed to age‐related neuropathologies , 2018, Annals of neurology.

[2]  O. Andreassen,et al.  Dissecting the genetic relationship between cardiovascular risk factors and Alzheimer’s disease , 2018, Acta Neuropathologica.

[3]  S. Leurgans,et al.  ATTRIBUTABLE RISK OF ALZHEIMER’S DEMENTIA DUE TO AGE-RELATED NEUROPATHOLOGIES , 2018, Alzheimer's & Dementia.

[4]  Alzheimer’s Disease Neuroimaging Initiative,et al.  Genome-wide significant risk factors on chromosome 19 and the APOE locus , 2018, Oncotarget.

[5]  J. Gallacher,et al.  Meta-analysis of genetic association with diagnosed Alzheimer’s disease identifies novel risk loci and implicates Abeta, Tau, immunity and lipid processing , 2018, bioRxiv.

[6]  W. M. van der Flier,et al.  Genetic meta-analysis identifies 9 novel loci and functional pathways for Alzheimer’s disease risk , 2018, bioRxiv.

[7]  A. Charidimou,et al.  Cerebral amyloid angiopathy, cerebral microbleeds and implications for anticoagulation decisions: The need for a balanced approach , 2018, International journal of stroke : official journal of the International Stroke Society.

[8]  A. Singleton,et al.  Alzheimer risk loci and associated neuropathology in a population-based study (Vantaa 85+) , 2018, Neurology: Genetics.

[9]  Nick C Fox,et al.  Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease , 2017, Nature Genetics.

[10]  K. Lunetta,et al.  Transethnic genome-wide scan identifies novel Alzheimer's disease loci , 2017, Alzheimer's & Dementia.

[11]  M. Sweet,et al.  SCIMP is a transmembrane non-TIR TLR adaptor that promotes proinflammatory cytokine production from macrophages , 2017, Nature Communications.

[12]  M. Esteller,et al.  Whole exome sequencing of Rett syndrome-like patients reveals the mutational diversity of the clinical phenotype , 2016, Human Genetics.

[13]  Kevin L. Boehme,et al.  Assessment of the genetic variance of late-onset Alzheimer's disease , 2016, Neurobiology of Aging.

[14]  Nick C Fox,et al.  Analysis of shared heritability in common disorders of the brain , 2018, Science.

[15]  Nick C Fox,et al.  Shared genetic contribution to ischemic stroke and Alzheimer's disease , 2016, Annals of neurology.

[16]  M. Carrillo,et al.  Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective , 2015, Alzheimer's & Dementia.

[17]  Margaret A. Pericak-Vance,et al.  Genome-Wide Association Meta-analysis of Neuropathologic Features of Alzheimer's Disease and Related Dementias , 2014, PLoS genetics.

[18]  Ronald C. Petersen,et al.  HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer’s disease in a three cohorts study , 2014, Molecular Psychiatry.

[19]  Nick C Fox,et al.  Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease , 2014, PLoS ONE.

[20]  Danielle A. Simmons,et al.  Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice , 2014, Nature Medicine.

[21]  Nick C Fox,et al.  Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.

[22]  Oscar L. Lopez,et al.  Design of a comprehensive Alzheimer’s disease clinic and research center in Spain to meet critical patient and family needs , 2013, Alzheimer's & Dementia.

[23]  A. Mauleon,et al.  ATP5H/KCTD2 locus is associated with Alzheimer's disease risk , 2013, Molecular Psychiatry.

[24]  L. Tran,et al.  Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease , 2013, Cell.

[25]  L. Cortellini,et al.  Genetic variation at CR1 increases risk of cerebral amyloid angiopathy , 2012, Neurology.

[26]  B. Hyman,et al.  Neuropathological alterations in Alzheimer disease. , 2011, Cold Spring Harbor perspectives in medicine.

[27]  D. Avramopoulos Genetics of Alzheimer's disease: recent advances , 2009, Genome Medicine.

[28]  R. Weller,et al.  Microvasculature changes and cerebral amyloid angiopathy in Alzheimer’s disease and their potential impact on therapy , 2009, Acta Neuropathologica.

[29]  C. Tzourio,et al.  Vascular risk factors and dementia , 2009, Neurology.

[30]  A. Francia,et al.  Screening of a microvascular endothelial cDNA library identifies rabaptin 5 as a novel autoantigen in Alzheimer's disease , 2007, Journal of Neuroimmunology.

[31]  Kathryn Ziegler-Graham,et al.  Forecasting the global burden of Alzheimer’s disease , 2007, Alzheimer's & Dementia.

[32]  G. Livingston,et al.  Relationship of vascular risk to the progression of Alzheimer disease , 2006, Neurology.

[33]  Satoshi Yasuda,et al.  Molecular machinery for non-vesicular trafficking of ceramide , 2003, Nature.

[34]  J. Rommens,et al.  Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. , 1996, Human molecular genetics.

[35]  D. Pollen,et al.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.

[36]  M. Yamada,et al.  Cerebral amyloid angiopathy. , 2012, Progress in molecular biology and translational science.

[37]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[38]  Amos D. Korczyn,et al.  Vascular dementia , 1993, Journal of the Neurological Sciences.

[39]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[40]  O. Levin,et al.  [Cerebral amyloid angiopathy]. , 2014, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.